Leerink affirms Heron Therapeutics (Nasdaq: HRTX) at Outperform with a price target of $33 following FDA approval of Sustol for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE